VK-1727, a selective small molecule inhibitor of EBNA1, reduces the DNA binding activity of EBNA1 while simultaneously restricting the proliferation and metabolic activity of EBV-positive cells, it does so without influencing the viability of EBV-negative cells, thereby demonstrating specificity. VK-1727 is primarily employed in researchs that focus on multiple sclerosis, in which it serves as a tool compound to interrogate EBNA1-mediated mechanisms in disease-related processes.